Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dice Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | Apr 22, 2024
Finance
Delisting biotechs take AIM at U.K. exchange
What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs
BioCentury | Jan 4, 2024
Deals
Parsing premiums: 2023’s biopharma M&A deals
2023’s highest-premium takeouts and its top-value deal all came early, but 4Q was notable for its pace of $1B+ deals
BioCentury | Jan 4, 2024
Management Tracks
Lanthaler leaving Evotec as CEO
Plus: Morphic’s CEO Tipirneni returns and more from Kojin, Harvard, Star, Novavax, Entrada, Brii, Switch, SmartCella
BioCentury | Sep 20, 2023
Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
BioCentury | Aug 30, 2023
Finance
IPO superstars
Back to School 2023: Six companies with NASDAQ IPOs since 2021 have more than doubled their market caps. Another four met the doubling mark via M&A
BioCentury | Jul 5, 2023
Finance
Deals drive XBI rebound in 2Q
Could the long-awaited recovery for biotech be signaling its start?
BioCentury | Jun 20, 2023
Deals
Despite IRA, Lilly’s Ricks finds path to value in Dice’s small molecules
$2.4B deal gives Lilly autoimmune programs that complement Taltz, and a platform to make more oral therapies
BioCentury | Oct 14, 2022
Finance
Oct. 13 Quick Takes: Epic $168M round for Glick’s Odyssey
Plus Dice raises $300M on back of data, Liu’s Prime Medicine seeking $1.6B valuation, and updates from VectivBio, CSPC, Relmada and more
BioCentury | Oct 12, 2022
Product Development
Oral therapy sees a new hopeful for immune diseases in Dice’s DC-806
The small molecule against IL-17 could bring competition to TYK2 inhibitors
Items per page:
1 - 10 of 13